Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

482
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
482
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

803
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
803
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.8K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.8K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

488
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
488
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

468
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
468

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significance of an Early Repeat Troponin Measurement Upon Presentation to the Hospital for Acute Heart Failure.

Journal of the American Heart Association·2024
Same author

Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases.

American heart journal plus : cardiology research and practice·2024
Same author

Natriuretic Peptide-guided Therapy for Heart Failure.

Heart international·2023
Same author

Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.

JACC. Heart failure·2022
Same author

Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study.

Clinical chemistry·2022
Same author

Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol.

Clinical and experimental emergency medicine·2022

Related Experiment Video

Updated: Apr 17, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K

ST2 and multimarker testing in acute decompensated heart failure.

Alexandre Mebazaa1, Salvatore Di Somma2, Alan S Maisel3

  • 1Université Paris Diderot, PRES Sorbonne Paris Cité and Saint Louis Lariboisière University Hospitals, Paris, France.

The American Journal of Cardiology
|February 21, 2015
PubMed
Summary

Predicting outcomes in acute decompensated heart failure (ADHF) is challenging. Combining biomarkers like soluble suppression of tumorigenicity 2 (ST2) with others improves risk prediction for ADHF patients.

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K
Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation
09:05

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

20.4K

Related Experiment Videos

Last Updated: Apr 17, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K
Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation
09:05

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

20.4K

Area of Science:

  • Biomarker discovery and validation
  • Cardiovascular medicine
  • Clinical diagnostics

Background:

  • Risk prediction in acute decompensated heart failure (ADHF) is complex due to heterogeneous patient presentations and underlying causes.
  • Existing data primarily focuses on chronic heart failure, leaving a gap in prognostic tools for acute settings.
  • Soluble suppression of tumorigenicity 2 (ST2) is a recognized independent predictor of outcomes in ADHF.

Purpose of the Study:

  • To evaluate the incremental prognostic value of combining ST2 with other biomarkers in ADHF patients.
  • To assess the utility of combined biomarkers for risk stratification in ADHF.
  • To explore the clinical and pathophysiological implications of biomarker combinations in ADHF.

Main Methods:

  • Analysis of data from large observational studies, including the ProBNP Investigation of Dyspnea in the Emergency Department and the Multinational Observational Cohort on Acute Heart Failure.
  • Evaluation of ST2 in conjunction with other biomarkers (e.g., C-reactive protein, midregional pro-adrenomedulin) for outcome prediction.
  • Statistical modeling to determine the independent and combined predictive power of biomarkers for short- and long-term outcomes.

Main Results:

  • Elevated ST2 levels, alone and in combination with other biomarkers, demonstrate significant prognostic value in ADHF.
  • Combining ST2 with C-reactive protein improved risk classification compared to ST2 alone in ADHF patients.
  • Midregional pro-adrenomedulin also showed independent value in predicting 30-day and 1-year outcomes in ADHF.

Conclusions:

  • Combination biomarker strategies, particularly involving ST2, offer enhanced risk prediction and stratification for ADHF.
  • Biomarker combinations may provide deeper pathophysiological insights into ADHF.
  • Further research into combined biomarker panels is warranted for clinical application in ADHF management.